MedTrace Logo

Gout Dose Response Study

NCT00955981 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2014-03-07

No results posted yet for this study

Summary

To compare the proportion of subjects whose serum urate (sUA) level is \< 6.0 mg/dL after 28 days of dosing by treatment group.

Conditions

  • Hyperuricemia

Interventions

DRUG

RDEA594

Uricosuric agent for the treatment of gout

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Vijay Hingorani, MD, PhD, MBA · Ardea Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-03-31
Completion
2011-09-30

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Georgia
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955981 on ClinicalTrials.gov